What should be the primary target of "treat to target" in psoriatic arthritis?
<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...
المؤلفون الرئيسيون: | Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Journal of Rheumatology
2018
|
مواد مشابهة
-
What should be the primary target of ‘treat to target’ in PsA?
حسب: Coates, L, وآخرون
منشور في: (2018) -
Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
حسب: Coates, L, وآخرون
منشور في: (2022) -
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
حسب: Coates, L, وآخرون
منشور في: (2019) -
Sustained very low disease activity and remission in psoriatic arthritis patients
حسب: Lubrano, E, وآخرون
منشور في: (2019) -
New approved drugs for psoriatic arthritis
حسب: F.M. Perrotta, وآخرون
منشور في: (2016-09-01)